A Phase 3 interventional study of Trastuzumab and Doxorubicin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 36 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 56th largest by enrollment of the 366 interventional ones that give a count, is one of 11 that started in 2002, is one of 60 in phase 3, and was the 212th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 11 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 49th largest by enrollment of the 170 interventional ones that give a count, is one of 5 that started in 2002, is one of 61 in phase 3, and was the 121st registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel observational study patients with HER2-negative disease will receive the same chemotherapy without Herceptin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m\^2), IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m\^2, IV; methotrexate 40 mg/m\^2, IV; and 5-fluorouracil 600 mg/m\^2, IV, on Day 1 of Cycles 8 through 10.
Drug: Trastuzumab · Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF
Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF
Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF
8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
Also known as: Herceptin
60 mg/m2 IV on Day 1 of Cycles 1 through 3
150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Event-Free Survival (EFS) - Percentage of Participants With an Event
EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.
Time frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Event-Free Survival
The median time, in months, between randomization and date of documented occurrence of an EFS event.
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Event Free at 1 Year
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Event Free at 2 Years
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Event Free at 3 Years
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants With Breast Pathological Complete Response (bpCR)
bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.
Time frame: BL, Day 1 of Cycles 1-10 (pre-surgery)
Percentage of Participants With Total Pathological Complete Response (tpCR)
tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.
Time frame: BL, Day 1 of Cycles 1-10 (pre-surgery)
Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.
Time frame: BL, Presurgery: Day 1 of Cycles 1-10
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the date of randomization to the date of the death due to any cause.
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Overall Survival
OS was defined as the time from the date of randomization to the date of the death due to any cause.
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Surviving at 1 Year
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Surviving at 2 Years
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Percentage of Participants Surviving at 3 Years
Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
| Milestone | HER2+ Trastuzumab/Doxorubicin/Paclitaxel/CMF (HER2+TC) | HER2+ Doxorubicin/Paclitaxel/CMF (HER2+C) | HER2- Doxorubicin/Paclitaxel/CMF (HER2-C) |
|---|---|---|---|
| Started | 115 | 116 | 99 |
| Completed | 1 | 2 | 1 |
| Not completed | 114 | 114 | 98 |
| Withdrew: Participants ongoing in follow-up | 77 | 60 | 58 |
| Withdrew: Death | 21 | 30 | 17 |
| Withdrew: Lack of efficacy | 10 | 9 | 8 |
| Withdrew: Failure to return | 0 | 2 | 4 |
| Withdrew: Violation of selection criteria | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 | 3 |
| Withdrew: Administrative/other | 2 | 1 | 3 |
| Withdrew: Other | 3 | 8 | 4 |
EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Event-Free Survival (EFS) - Percentage of Participants With an Event | 40.0 (47.7 to NA) | 50.9 (24.1 to NA) | 42.4 (57.7 to NA) |
bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants With Breast Pathological Complete Response (bpCR) | 44.3 (35.1 to 53.9) | 26.7 (18.9 to 35.7) | 19.2 (12.0 to 28.3) |
tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants With Total Pathological Complete Response (tpCR) | 40.0 (31.0 to 49.6) | 20.7 (13.7 to 29.2) | 18.2 (11.1 to 27.2) |
Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria | 72.7 (63.4 to 80.8) | 66.4 (56.6 to 75.2) | 65.6 (55.2 to 75.0) |
OS was defined as the time from the date of randomization to the date of the death due to any cause.
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 19.1 (NA to NA) | 28.4 (58.2 to NA) | 21.2 (NA to NA) |
The median time, in months, between randomization and date of documented occurrence of an EFS event.
| months | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Event-Free Survival | NA (47.7 to NA) | 43.6 (24.1 to NA) | 64.5 (57.7 to NA) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Event Free at 1 Year | 89 (84 to 95) | 82 (74 to 89) | 80 (73 to 88) |
OS was defined as the time from the date of randomization to the date of the death due to any cause.
| months | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Overall Survival | NA (NA to NA) | NA (58.2 to NA) | NA (NA to NA) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Surviving at 1 Year | 100 (100 to 100) | 99 (97 to 100) | 97 (93 to 100) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Event Free at 2 Years | 73 (64 to 81) | 61 (51 to 70) | 69 (60 to 78) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Surviving at 2 Years | 95 (91 to 99) | 88 (82 to 94) | 90 (83 to 96) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Event Free at 3 Years | 65 (56 to 74) | 52 (43 to 62) | 63 (53 to 72) |
| percentage of participants | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Percentage of Participants Surviving at 3 Years | 85 (79 to 92) | 78 (70 to 86) | 85 (78 to 92) |
Collected over BL, presurgery treatment Cycles 1-10, postsurgery Cycles 1-17, every 6 months thereafter for up to 60 months; yearly thereafter until primary analysis has taken place, after which serious adverse events were collected only if treatment related.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HER2+ TC | — | 18/115 (15.7%) | 113/115 (98.3%) |
| HER2+ C | — | 8/112 (7.1%) | 112/112 (100%) |
| HER2- C | — | 9/99 (9.1%) | 98/99 (99%) |
| Event | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 7/115 | 3/112 | 3/99 |
| Deep vein thrombosisVascular disorders | 0/115 | 3/112 | 0/99 |
| PyrexiaGeneral disorders | 3/115 | 0/112 | 0/99 |
| NeutropeniaBlood and lymphatic system disorders | 1/115 | 2/112 | 0/99 |
| DiarrhoeaGastrointestinal disorders | 0/115 | 2/112 | 0/99 |
| NauseaGastrointestinal disorders | 0/115 | 2/112 | 0/99 |
| PneumoniaInfections and infestations | 2/115 | 0/112 | 1/99 |
| Ejection fraction decreasedInvestigations | 2/115 | 0/112 | 0/99 |
| StomatitisGastrointestinal disorders | 0/115 | 1/112 | 1/99 |
| Herpes zosterInfections and infestations | 0/115 | 0/112 | 1/99 |
| Event | HER2+ TC | HER2+ C | HER2- C |
|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 91/115 | 87/112 | 90/99 |
| NauseaGastrointestinal disorders | 88/115 | 88/112 | 70/99 |
| AstheniaGeneral disorders | 52/115 | 58/112 | 32/99 |
| VomitingGastrointestinal disorders | 54/115 | 52/112 | 36/99 |
| StomatitisGastrointestinal disorders | 46/115 | 44/112 | 21/99 |
| MyalgiaMusculoskeletal and connective tissue disorders | 35/115 | 25/112 | 31/99 |
| DiarrhoeaGastrointestinal disorders | 35/115 | 32/112 | 18/99 |
| ConjunctivitisEye disorders | 34/115 | 22/112 | 7/99 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 34/115 | 26/112 | 19/99 |
| ParaesthesiaNervous system disorders | 22/115 | 29/112 | 22/99 |
Safety population: all participants who were randomized for the main study or registered for the observational parallel study and who received study medication at least once. Groups were analyzed as randomized/registered. Age was missing for 1 participant in the HER2+ TC treatment group.
| Age, Continuous(years) | HER2+ TC | HER2+ C | HER2- C | Total |
|---|---|---|---|---|
| Mean | 50.2 ± 9.78 | 52.3 ± 10.97 | 50.6 ± 10.46 | 51.0 ± 10.42 |
| Sex: Female, Male(Participants) | HER2+ TC | HER2+ C | HER2- C | Total |
|---|---|---|---|---|
| Female | 115 | 112 | 99 | 326 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of May 2002, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab